BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 15983549)

  • 1. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
    Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
    Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
    Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
    Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
    Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
    Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J
    Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
    Neumann F; Graef T; Tapprich C; Vaupel M; Steidl U; Germing U; Fenk R; Hinke A; Haas R; Kobbe G
    Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
    Bornhäuser M; Schuler U; Pörksen G; Naumann R; Geissler G; Thiede C; Schwerdtfeger R; Ehninger G; Thiede HM
    Transplantation; 1999 Feb; 67(4):499-504. PubMed ID: 10071016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
    Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
    Zhu X; Lai X; Luo Y; Shi J; Tan Y; Zheng W; He J; Xie W; Li L; Zhang J; Ye X; Lin M; Cai Z; Huang H
    Leuk Res; 2013 Sep; 37(9):1046-51. PubMed ID: 23849987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
    Rodriguez R; Parker P; Nademanee A; Smith D; O'Donnell MR; Stein A; Snyder DS; Fung HC; Krishnan AY; Popplewell L; Cohen S; Somlo G; Angelopoulou M; Al-Kadhimi Z; Falk PM; Spielberger R; Kogut N; Sahebi F; Senitzer D; Slovak M; Schriber J; Forman SJ
    Bone Marrow Transplant; 2004 Jun; 33(11):1123-9. PubMed ID: 15064696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
    Baron F; Sandmaier BM; Storer BE; Maris MB; Langston AA; Lange T; Petersdorf E; Bethge W; Maziarz RT; McSweeney PA; Pulsipher MA; Wade JC; Chauncey TR; Shizuru JA; Sorror ML; Woolfrey AE; Maloney DG; Storb R
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1041-8. PubMed ID: 17697966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
    Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation.
    Miyamoto T; Takashima S; Kato K; Takase K; Yoshimoto G; Yoshida S; Henzan H; Osaki K; Kamimura T; Iwasaki H; Eto T; Teshima T; Nagafuji K; Akashi K
    Int J Hematol; 2017 Jan; 105(1):92-99. PubMed ID: 27686673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.